Overview

* Neuronetics Q3 2025 revenue rose 101% yr/yr but missed analyst expectations

* U.S. Greenbrook clinic revenue grew 25% on an adjusted pro forma basis

* CEO Keith J. Sullivan to retire in June 2026, search for successor underway

Outlook

* Company expects Q4 2025 revenue between $40 mln and $43 mln

* Neuronetics ( STIM ) revises 2025 revenue guidance to $147 mln-$150 mln

* Company targets positive cash flow from operations in Q4 2025

Result Drivers

* GREENBROOK ACQUISITION - Revenue growth primarily driven by Greenbrook clinic acquisition

* PURCHASING PATTERNS - Decline in treatment session revenue due to changes in customer purchasing patterns

* CASH MANAGEMENT - Improved cash management with reduced cash used in operations

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $37.30 $37.80

Revenue mln mln (3

Analysts

)

Q3 EPS -$0.13

Q3 Gross 45.90%

Margin

Q3 $24.40

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for Neuronetics Inc ( STIM ) is $7.00, about 60.4% above its November 3 closing price of $2.77

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)